May 8, 2019 / 5:34 AM / 18 days ago

BRIEF-Novartis Says Data Show Mayzent's Positive Impact On Cognitive Processing Speed

May 8 (Reuters) - Novartis AG:

* NOVARTIS DATA AT AAN SHOW MAYZENT’S® POSITIVE IMPACT ON COGNITIVE PROCESSING SPEED, A CORE ELEMENT OF COGNITIVE FUNCTION, IN PEOPLE LIVING WITH SECONDARY PROGRESSIVE MS

* DATA FROM EXPAND - THE LARGEST RANDOMIZED CONTROLLED TRIAL IN A REPRESENTATIVE SECONDARY PROGRESSIVE MS (SPMS) POPULATION - SHOW MAYZENT® (SIPONIMOD) HAD A MEANINGFUL BENEFIT ON COGNITIVE PROCESSING SPEED (CPS) FOR THESE PATIENTS

* IMPAIRMENT IN COGNITIVE FUNCTION, ONE OF THE MOST DISABLING ASPECTS OF MS, AFFECTS 50-70% OF PATIENTS AND IS MORE SEVERE IN PATIENTS WITH SPMS

* EXPAND FINDINGS DEMONSTRATE THAT SPMS PATIENTS TREATED EARLIER IN THE COURSE OF THEIR DISEASE BENEFITED MOST, SUGGESTING EARLY TREATMENT LEADS TO BETTER COGNITIVE OUTCOMES Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below